Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,420.50 DKK | +1.00% |
|
+1.86% | -4.82% |
16/07 | Genmab A/S Announces Sales Results of Darzalex for Second Quarter of 2025 | CI |
16/07 | Genmab says net sales of Darzalex in Q2 $3,539 mln | RE |
Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|---|---|---|
Revenues | 1.01TCr | 848.2Cr | 1.46TCr | 1.65TCr | 2.15TCr | |||||
Total Revenues | 1.01TCr | 848.2Cr | 1.46TCr | 1.65TCr | 2.15TCr | |||||
Cost of Goods Sold, Total | - | - | - | 23Cr | 98Cr | |||||
Gross Profit | 1.01TCr | 848.2Cr | 1.46TCr | 1.62TCr | 2.05TCr | |||||
Selling General & Admin Expenses, Total | 66Cr | 128.3Cr | 267.6Cr | 329.7Cr | 379Cr | |||||
R&D Expenses | 311.5Cr | 418.1Cr | 552.4Cr | 763Cr | 967.2Cr | |||||
Other Operating Expenses, Total | 377.6Cr | 546.4Cr | 820Cr | 1.09TCr | 1.35TCr | |||||
Operating Income | 633.5Cr | 301.8Cr | 639.5Cr | 532.1Cr | 707.9Cr | |||||
Interest Expense, Total | -1Cr | -1.3Cr | -2.1Cr | -2.7Cr | -12Cr | |||||
Interest And Investment Income | 18Cr | 20Cr | 32Cr | 94Cr | 100Cr | |||||
Net Interest Expenses | 17Cr | 18Cr | 30Cr | 91Cr | 88Cr | |||||
Currency Exchange Gains (Loss) | -145.6Cr | 147Cr | 103.4Cr | -89Cr | 133.9Cr | |||||
Other Non Operating Income (Expenses) | - | - | - | - | - | |||||
EBT, Excl. Unusual Items | 505.3Cr | 467.2Cr | 773.2Cr | 534.4Cr | 929.3Cr | |||||
Merger & Related Restructuring Charges | - | - | - | - | -30Cr | |||||
Gain (Loss) On Sale Of Investments | 87Cr | -69Cr | -66Cr | 29Cr | 25Cr | |||||
Asset Writedown | -2.2Cr | - | -3.8Cr | - | -7.6Cr | |||||
Other Unusual Items | - | - | - | - | - | |||||
EBT, Incl. Unusual Items | 590.4Cr | 398.3Cr | 703.5Cr | 563.7Cr | 916.4Cr | |||||
Income Tax Expense | 114.6Cr | 98Cr | 151.3Cr | 128.5Cr | 132Cr | |||||
Earnings From Continuing Operations | 475.8Cr | 300.8Cr | 552.2Cr | 435.2Cr | 784.4Cr | |||||
Net Income to Company | 475.8Cr | 300.8Cr | 552.2Cr | 435.2Cr | 784.4Cr | |||||
Net Income - (IS) | 475.8Cr | 300.8Cr | 552.2Cr | 435.2Cr | 784.4Cr | |||||
Net Income to Common Incl Extra Items | 475.8Cr | 300.8Cr | 552.2Cr | 435.2Cr | 784.4Cr | |||||
Net Income to Common Excl. Extra Items | 475.8Cr | 300.8Cr | 552.2Cr | 435.2Cr | 784.4Cr | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 73 | 46 | 84.45 | 66.64 | 122.21 | |||||
Basic EPS - Continuing Operations | 73 | 46 | 84.45 | 66.64 | 122.21 | |||||
Basic Weighted Average Shares Outstanding | 6.52Cr | 6.54Cr | 6.54Cr | 6.53Cr | 6.42Cr | |||||
Net EPS - Diluted | 72.21 | 45.54 | 83.65 | 66.02 | 121.36 | |||||
Diluted EPS - Continuing Operations | 72.21 | 45.54 | 83.65 | 66.02 | 121.36 | |||||
Diluted Weighted Average Shares Outstanding | 6.59Cr | 6.6Cr | 6.6Cr | 6.59Cr | 6.46Cr | |||||
Normalized Basic EPS | 48.45 | 44.65 | 73.91 | 51.14 | 90.49 | |||||
Normalized Diluted EPS | 47.93 | 44.21 | 73.21 | 50.67 | 89.86 | |||||
American Depositary Receipts Ratio (ADR) | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | |||||
Supplemental Items | ||||||||||
EBITDA | 656.5Cr | 326.6Cr | 671.9Cr | 556.1Cr | 739Cr | |||||
EBITA | 644.4Cr | 310.2Cr | 646.5Cr | 537.6Cr | 715.7Cr | |||||
EBIT | 633.5Cr | 301.8Cr | 639.5Cr | 532.1Cr | 707.9Cr | |||||
EBITDAR | 656.8Cr | 326.7Cr | - | - | - | |||||
Effective Tax Rate - (Ratio) | 19.41 | 24.48 | 21.51 | 22.8 | 14.4 | |||||
Current Domestic Taxes | 119.1Cr | 97Cr | 149.8Cr | - | - | |||||
Total Current Taxes | 119.1Cr | 97Cr | 149.8Cr | 130.1Cr | 179.9Cr | |||||
Deferred Domestic Taxes | -4.5Cr | 70L | 1.5Cr | - | - | |||||
Total Deferred Taxes | -4.5Cr | 70L | 1.5Cr | -1.6Cr | -48Cr | |||||
Normalized Net Income | 315.81Cr | 292Cr | 483.25Cr | 334Cr | 580.81Cr | |||||
Interest on Long-Term Debt | 1Cr | 1.3Cr | 2.1Cr | 2.7Cr | 12Cr | |||||
Supplemental Operating Expense Items | ||||||||||
General and Administrative Expenses | 66Cr | - | - | - | - | |||||
Research And Development Expense From Footnotes | 313.7Cr | 418.1Cr | 556.2Cr | 763Cr | 974.8Cr | |||||
Net Rental Expense, Total | 30L | 10L | - | - | - | |||||
Imputed Operating Lease Interest Expense | 10L | 3L | - | - | - | |||||
Imputed Operating Lease Depreciation | 20.4L | 7L | - | - | - | |||||
Stock-Based Comp., G&A Exp. (Total) | - | - | - | - | - | |||||
Stock-Based Comp., Other (Total) | 20Cr | 31Cr | 44Cr | 59Cr | 72Cr | |||||
Total Stock-Based Compensation | 20Cr | 31Cr | 44Cr | 59Cr | 72Cr |
- Stock Market
- Equities
- GMAB Stock
- Financials Genmab A/S
- Income Statement
Select your edition
All financial news and data tailored to specific country editions

MarketScreener is also available in this country: United States.
Switch edition